Strategies for enhancing specificity and efficacy of oncolytic viruses in cancer treatment
Related Experiment Video
Updated: Apr 20, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Khakimov Murod1, Yarmukhamedova Saodat2, Intizor Avazmetova3
1Department of Faculty and Hospital Surgery, Tashkent State Medical University, Tashkent, Uzbekistan.
Abstract:
Oncolytic viruses (OVs) are designed to selectively infect, proliferate within, and destroy cancer cells while concurrently eliciting robust antitumor immune responses. Notwithstanding their significant potential, inadequate tumor selectivity and restricted treatment efficacy persist as substantial barriers to wider clinical utilization. This review rigorously evaluates current advancements in OV engineering designed to address these issues. Transcriptional targeting, which employs tumor-specific promoters like hTERT, E2F1, and hypoxia-inducible elements, microRNA detargeting, and the redirection of viral entry towards tumor-associated antigens such as EGFR, HER2, and EpCAM, alongside multi-layered logic-gated regulatory systems, represent strategies to augment tumor specificity. To bolster anticancer efficacy, OVs have been modified with immunomodulatory agents, including cytokines (GM-CSF, IL-12), immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4), chemokines, and stroma-degrading enzymes (hyaluronidase, relaxin). Subsequent advancements encompass nanoparticle encapsulation, carrier-cell transport mechanisms, metabolic reprogramming strategies, and synergistic combinations with immunotherapy, chemotherapy, or radiotherapy. Furthermore, systems and synthetic biology techniques are enabling the development of advanced "smart" OVs, which possess the capacity for real-time detection and adaptation within the tumor microenvironment. These combined methodologies present considerable promise for enhancing the safety profile, intratumoral distribution, and overall therapeutic efficacy of oncolytic virotherapy.
Insights
Oncolytic viruses (OVs) are engineered to target cancer cells and stimulate immune responses. Enhancements in OV technology improve tumor selectivity and treatment effectiveness for better cancer therapy.
Area of Science:
- Oncolytic virotherapy
- Cancer immunology
- Synthetic biology
Background:
- Oncolytic viruses (OVs) show promise for cancer treatment by selectively destroying tumor cells and activating anti-cancer immunity.
- Current limitations include insufficient tumor selectivity and restricted therapeutic efficacy, hindering widespread clinical application.
Purpose of the Study:
- To review recent advancements in engineering oncolytic viruses (OVs) to overcome limitations in tumor selectivity and treatment efficacy.
- To explore novel strategies for enhancing the safety, distribution, and overall therapeutic potential of OVs.
Main Methods:
- Engineering strategies discussed include transcriptional targeting (e.g., hTERT, E2F1 promoters), microRNA detargeting, and redirection of viral entry towards tumor antigens (e.g., EGFR, HER2).
- Modifications for enhanced efficacy involve incorporating immunomodulatory agents (cytokines, checkpoint inhibitors), stroma-degrading enzymes, and synergistic combinations with other therapies.
- Advanced approaches like nanoparticle encapsulation, carrier-cell transport, metabolic reprogramming, and systems/synthetic biology for "smart" OVs are also evaluated.
Main Results:
- Engineered OVs demonstrate improved tumor specificity through targeted promoters, detargeting mechanisms, and logic-gated systems.
- Enhanced anticancer efficacy is achieved by equipping OVs with immunomodulatory payloads and combining them with conventional treatments.
- Novel delivery systems and "smart" OV designs promise better intratumoral distribution and adaptive responses within the tumor microenvironment.
Conclusions:
- Engineering strategies significantly enhance the tumor selectivity and therapeutic efficacy of oncolytic viruses.
- Advanced OV designs, including "smart" OVs, hold considerable promise for improving safety, distribution, and clinical outcomes in cancer therapy.
- Continued development in OV engineering is crucial for realizing the full potential of oncolytic virotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...